arbiter
JournalsAccount

Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan

Chanon Nusawat et al.

European Journal of Health Economics2026https://doi.org/10.1007/s10198-026-01912-9article
AJG 2ABDC A
Weight
0.50

Abstract

Pembrolizumab is a cost-effective first-line treatment for advanced NSCLC with PD-L1 TPS ≥ 50% in Japan. Nivolumab plus ipilimumab is also a viable option. Atezolizumab is the least cost-effective.

Open via your library →

Cite this paper

https://doi.org/https://doi.org/10.1007/s10198-026-01912-9

Or copy a formatted citation

@article{chanon2026,
  title        = {{Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan}},
  author       = {Chanon Nusawat et al.},
  journal      = {European Journal of Health Economics},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1007/s10198-026-01912-9},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.